Drug-Test Retesting, Split Specimens, and Disputes

The most useful way to review a disputed drug test is usually to follow the program’s established procedure promptly. That may include medical review, testing a retained split specimen, reviewing collection records, or appealing under a workplace, clinical, or court process.

This article provides general U.S. information, not legal advice. Start with Understanding Drug-Test Results.

Retest can mean different things

  • Reanalysis: the original specimen is tested again by the same laboratory.
  • Split-specimen test: a separately sealed portion of the original collection is sent to another qualified laboratory.
  • New collection: a different specimen is obtained at a later time.
  • Confirmatory testing: a specific method tests the original specimen after an initial screen.

These steps answer different questions and should not be treated as interchangeable.

Why a new negative may not disprove an earlier positive

A new specimen reflects a new collection time. Drug and metabolite concentrations change, specimens have different windows, and panels or cutoffs may differ. A later negative can coexist with a valid earlier positive. Testing a retained portion of the original specimen is often more directly relevant to the original finding.

Split-specimen testing

In programs that use split specimens, the original collection is divided and sealed. After certain verified results, the donor may request that the second bottle be tested at another qualified laboratory. The governing rule controls the request deadline, laboratory qualifications, analytes, reporting, and payment.

Split testing does not necessarily repeat every step in the same way as the first laboratory; it follows the applicable verification procedure.

Medical Review Officer process

Before disputing the laboratory, determine whether medical review is still open. A legitimate prescription, recent procedure, or product may be relevant. Provide authentic documentation promptly through the authorized channel. Do not send a full medication history to unnecessary recipients.

Records that may matter

  • the final laboratory and verified result;
  • the custody and control form or chain-of-custody record;
  • collection-site documentation;
  • specimen-validity findings;
  • the panel, methods, analytes, and cutoffs;
  • MRO notices and documentation requests; and
  • the written policy, court order, or regulation governing the test.

Access rights vary, and some analytical material may require a formal request.

Grounds for review

A meaningful review focuses on evidence: identity or labeling problems, chain-of-custody gaps, an unconfirmed screen, inappropriate laboratory or method, a legitimate medical explanation, failure to follow policy, incorrect analyte interpretation, or denial of a required split-specimen process.

A general claim that the result “must be wrong” is less useful than a specific procedural or scientific issue.

Workplace disputes

Federal and DOT-regulated programs have detailed procedures. Nonregulated workplace rights depend on state law, employer policy, contracts, collective bargaining, and the facts. Deadlines may apply to offers, discipline, grievance procedures, or administrative complaints.

Clinical disputes

Ask the clinician which method and analytes were used and how the result affects care. Unexpected immunoassay results may justify definitive testing. A therapeutic conversation is preferable to assumptions, and urgent medication changes should be based on clinical safety.

Court and forensic disputes

Preservation of the specimen, disclosure, expert review, admissibility, and deadlines are jurisdiction specific. Obtain qualified legal advice promptly when liberty, custody, licensing, or other substantial rights are involved.

Practical steps

  1. Identify whether the result is presumptive, confirmed, or verified.
  2. Write down every deadline and authorized contact.
  3. Request the available split-specimen procedure when appropriate.
  4. Preserve notices, receipts, medication records, and communications.
  5. Avoid independent testing until you understand whether it will answer the disputed question.
  6. Seek professional advice proportional to the consequences.

Continue with Chain of Custody and Drug-Test Evidence and Appeals.

Sources

Last evidence review: October 29, 2026.